Modification. Subject to Section 3 herein, IDT may modify the terms of this Agreement at any time and such amended Agreement will supersede any previous agreement between Customer and IDT Energy. IDT will provide Customer thirty (30) days prior written notice of any such modification. After receipt of such notice, Customer may cancel the Agreement by providing written notice to IDT Energy before the commencement of the next billing cycle.
Modification. THE TERMS AND CONDITIONS OF THIS AGREEMENT CAN NOT BE MODIFIED OR AMENDED IN ANY WAY EXCEPT BY AGREEMENT OF BOTH PARTIES IN WRITING.
Modification. This Cooperation Agreement may be modified by mutual written agreement between the Parties, at the initiative of either of them. THIRTEENTH. Non-existence of a joint and several liability: There will be no joint and several liability between the Parties that execute this Cooperation Agreement, because each one will respond to third parties for the obligations that it specifically assumes. Each Party will indemnify and hold harmless the other Party for any sum the latter may be required to pay, or any damages or losses it may have suffered, as a result of a n action or omission of the latter. FOURTEENTH. Assignment: The Parties may not partially or fully assign this Cooperation Agreement to a third party, except with a written express authorization from the non-assigning Party. FIFTEENTH. Grounds for termination: This Cooperation Agreement will be terminated in advance, either during the initial term or any of its extensions, based on any of the following causes:
Modification. This Guaranty may be modified only in the case that written consent by Landlord is obtained.
Modification. This Guaranty may be modified only in the case that written consent by Xxxxxxxx is obtained.
Modification. The Protocol may not be unilaterally modified by the PRINCIPAL INVESTIGATOR; it requires prior approval and consent by the SPONSOR. Any modification to the authorized Protocol shall be notified to the relevant Ethics Committee, the Agencia Española de Medicamentos y Productos Sanitarios, and shall have the approval of the Principal Investigator of the Study. Any modifications or amendments to the Protocol shall be notified to the SITE, through the local DREC. The site may, if such modifications or amendments are considered as essential, either terminate the agreement or by mutual agreement with the Sponsor, proceed with the renewal of the contract. All the parties agree to comply with current Spanish Legislation regulating Clinical Trials with Drugs: Royal Legislative Decree 1/2015, of July 24, approving the revised text of the Law on guarantees and rational use of medicines and medical devices, Royal Decree 1090/2015 of December 4, regulating clinical trials with drugs, Royal Decree 577/2013 of 26 July , regulating pharmacovigilance of drugs for human use, the Convention on 4 April, 1997 for the Protection of Human Rights and Dignity of the Human Being with regard to the Application of Biology and Medicine, (instrument of ratification on 23JUL1999) date of entry into force in Spain 01JAN2000, and other consistent rules. Clinical trials with medical devices will be performed according to the Royal Decree 1591/2009 of 16 October, regulating medical devices and Royal Decree 1616/2009, of 26 October, regulating implantable active medical devices. It is agreed that the aforementioned clinical trials with medical devices will be performed in accordance with the provisions of the Declaration of Helsinki and the ICH guidelines (International Conference onHarmonization Guideline) for Good Clinical Practices (GCP). The SITE shall ensure that during the conduct of the Trial fundamental human rights are fully observed, in accordance with essential Bioethical standards, health standards and Good Clinical Practice standards applicable to the Trial, without substituting the tasks entrusted to the SPONSOR, INVESTIGATOR and Drug Research Ethics Committee. Likewise, the following shall apply: - Decree 17/2012, of 20 January, of the Consell [Cabinet of the Regional Government of Valencia], which amends Decree 73/2009 of 5 June, of the Consell, regulating the management of clinical trials and post-authorization observational studies with drugs and medical devices. - Resoluti...